Io Biotech Inc (IOBT) Stock Price, Quote & News

Company Profile

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to...

Industry: Biotechnology

Sector: Healthcare

Phone: 45 70 70 29 80

Website: www.iobiotech.com

Address:

Ole MaalOees Vej 3, Copenhagen N, Copenhagen, Denmark

Sha_B_Ral Mar. 17 at 11:11 PM

$RZLV It must not surge yet. Absolutely not!!!!!! 🤣🤣🤣🤣🤣 My average is about $4. I haven’t been able to lower my average yet. Until I buy more, please wait just a little longer. 😁😁😁😁😁 The treasures I found. 💪VXRT (Mind-blowing technology — with the government and Sanofi behind it.) 👍RZLV 👌DVLT (Innovative technology — it will shake up the financial market.) 🫶SLS (Amazing efficacy — on the verge of an explosion.) $IOBT It seems acquisition news is finally coming. I wonder if anyone has overlapping stocks with me? Haha~ May everyone become wealthy in 2026. 💸💸💰💰🪙🪙

0 · Reply

TerryMolenaar Mar. 17 at 7:59 PM

$IOBT buy when everybody is

0 · Reply

VinnyLaw Mar. 17 at 7:57 PM

$IOBT The fact is that until there’s support, this will keep falling. There’s no buying pressure to keep this afloat. Also, I’m wondering if even Cohen dumped his shares. There’s no reason for a dump unless it’s known that there will be no return on any investment after a sale of assets. I’m becoming very bearish about this situation. It’s sad because it has been mismanaged.

0 · Reply

GTMStox Mar. 17 at 7:52 PM

$IOBT wow this is definitely in the POS category at this point

0 · Reply

LordWorld Mar. 17 at 7:49 PM

$IOBT More than 140,000 shares purchased in 1 second

1 · Reply

GTMStox Mar. 17 at 6:02 PM

$IOBT After 7 red days, I don't mind a little green but this could also dump befoe EOD.

0 · Reply

LordWorld Mar. 17 at 4:18 PM

$IOBT The bottom is in ?

1 · Reply

LordWorld Mar. 17 at 2:24 PM

$IOBT

0 · Reply

LordWorld Mar. 17 at 2:23 PM

$IOBT Who keeps buying?????? 🟢 71500

0 · Reply

stevenryl86 Mar. 17 at 1:10 AM

$IOBT waking up on another dump, well it just hold and wait.

0 · Reply

IO Biotech Provides Corporate Update

Jan 21, 2026, 5:30 AM EST - 7 weeks ago

IO Biotech Announces Exploration of Strategic Alternatives

Dec 15, 2025, 4:05 PM EST - 3 months ago

IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications

Nov 26, 2025, 10:46 AM EST - 3 months ago

IO Biotech Announces Participation in Upcoming December Investor Conferences

Nov 14, 2025, 8:05 AM EST - 4 months ago

IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Nov 12, 2025, 8:30 AM EST - 4 months ago

IO Biotech Announces Participation in Upcoming Investor Conferences

Nov 7, 2025, 9:00 AM EST - 4 months ago

IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Oct 20, 2025, 2:30 AM EDT - 5 months ago

IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025

Sep 29, 2025, 7:05 AM EDT - 6 months ago

IO Biotech Provides Update Following Pre-BLA Meeting with FDA

Sep 23, 2025, 8:05 AM EDT - 6 months ago

IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025

Sep 9, 2025, 11:41 AM EDT - 6 months ago

IO Biotech, Inc. (IOBT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Aug 14, 2025, 4:05 PM EDT - 7 months ago

IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Aug 12, 2025, 4:17 PM EDT - 7 months ago

IO Biotech: A Buying Opportunity Following Phase 3 Readout In Melanoma

Aug 11, 2025, 8:24 AM EDT - 7 months ago

IO Biotech's cancer vaccine shows improvement in late-stage study goal

Aug 11, 2025, 8:00 AM EDT - 7 months ago

IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed

Aug 10, 2025, 8:00 AM EDT - 7 months ago

IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

May 20, 2025, 8:05 AM EDT - 10 months ago

IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference

May 14, 2025, 8:05 AM EDT - 10 months ago

IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights

Apr 26, 2025, 3:05 PM EDT - 11 months ago

IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025

Apr 25, 2025, 1:00 PM EDT - 11 months ago

IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170

Mar 25, 2025, 4:35 PM EDT - 1 year ago

IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 18, 2025, 8:00 AM EDT - 1 year ago

IO Biotech Named Among Fast Company's World's Most Innovative Companies of 2025

Mar 4, 2025, 4:17 PM EST - 1 year ago

IO Biotech Reports 2024 Business Highlights

Feb 23, 2025, 12:07 PM EST - 1 year ago

IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference

Feb 20, 2025, 8:05 AM EST - 1 year ago

IO Biotech to Present at the 45th Annual Cowen Health Care Conference

Feb 4, 2025, 8:05 AM EST - 1 year ago

IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate

Jan 9, 2025, 8:05 AM EST - 1 year ago

IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer

Dec 20, 2024, 8:05 AM EST - 1 year ago

IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank

Nov 12, 2024, 7:05 AM EST - 1 year ago

IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Nov 7, 2024, 10:00 AM EST - 1 year ago

IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study

Oct 4, 2024, 9:00 AM EDT - 1 year ago

IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Sep 14, 2024, 2:30 AM EDT - 1 year ago

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

Aug 30, 2024, 4:05 PM EDT - 1 year ago

IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

Aug 13, 2024, 7:05 AM EDT - 1 year ago

IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Jul 25, 2024, 4:05 PM EDT - 1 year ago

IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024

May 23, 2024, 8:30 AM EDT - 1 year ago

IO Biotech to Present at Jefferies Global Healthcare Conference

May 14, 2024, 7:55 AM EDT - 2 years ago

IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights

Apr 24, 2024, 4:30 PM EDT - 2 years ago

IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 15, 2024, 8:30 AM EDT - 2 years ago

IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness

Apr 9, 2024, 12:00 PM EDT - 2 years ago

IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103

Apr 5, 2024, 8:30 AM EDT - 2 years ago

IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer

Mar 6, 2024, 4:11 PM EST - 2 years ago

IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 5, 2024, 4:40 PM EST - 2 years ago

IO Biotech Announces 2023 Fourth-Quarter and Year-End Results

Feb 26, 2024, 4:05 PM EST - 2 years ago

IO Biotech to Present at 44th Annual Cowen Health Care Conference

Jan 3, 2024, 3:04 AM EST - 2 years ago

IO Biotech: A Phase 3 Company Getting No Respect

Dec 21, 2023, 8:30 AM EST - 2 years ago

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

Nov 13, 2023, 8:12 AM EST - 2 years ago

IO Biotech Announces 2023 Third Quarter Results

Nov 13, 2023, 8:00 AM EST - 2 years ago

IO Biotech Appoints Helen Collins, MD, to its Board of Directors

Nov 10, 2023, 8:00 AM EST - 2 years ago

IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

Nov 1, 2023, 8:30 AM EDT - 2 years ago

IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sha_B_Ral Mar. 17 at 11:11 PM

0 · Reply

TerryMolenaar Mar. 17 at 7:59 PM

$IOBT buy when everybody is

0 · Reply

VinnyLaw Mar. 17 at 7:57 PM

0 · Reply

GTMStox Mar. 17 at 7:52 PM

$IOBT wow this is definitely in the POS category at this point

0 · Reply

LordWorld Mar. 17 at 7:49 PM

$IOBT More than 140,000 shares purchased in 1 second

1 · Reply

GTMStox Mar. 17 at 6:02 PM

$IOBT After 7 red days, I don't mind a little green but this could also dump befoe EOD.

0 · Reply

LordWorld Mar. 17 at 4:18 PM

$IOBT The bottom is in ?

1 · Reply

LordWorld Mar. 17 at 2:24 PM

$IOBT

0 · Reply

LordWorld Mar. 17 at 2:23 PM

$IOBT Who keeps buying?????? 🟢 71500

0 · Reply

stevenryl86 Mar. 17 at 1:10 AM

$IOBT waking up on another dump, well it just hold and wait.

0 · Reply

GTMStox Mar. 16 at 7:43 PM

$IOBT I don't believe this company nor market is worried about "earnings" dates. They are fighting for survival.

0 · Reply

LordWorld Mar. 16 at 6:51 PM

$IOBT

0 · Reply

GTMStox Mar. 16 at 5:44 PM

$IOBT Asset sales seems to be best chance

1 · Reply

LordWorld Mar. 16 at 5:10 PM

$IOBT Qassim Ahmad failed his part of the job, so he was fired. He is an employee. All the other IOBT Founders, as well as other key figures in IOBT, are on the ground.

1 · Reply

GTMStox Mar. 16 at 4:53 PM

$IOBT I see some speak of buyout but I think that's nonsense. 3 scenarios IMO: 1. Reverse Merger 2. Private Placement announcement (Would show renewed faith in platform, although that seems unlikely since they don't even have a CMO) 3. Bankruptcy/Delisting I'm leaning towards reverse merger.

1 · Reply

LordWorld Mar. 16 at 4:23 PM

$IOBT

1 · Reply

LordWorld Mar. 16 at 4:23 PM

$IOBT $QNCX $AIB

0 · Reply

LordWorld Mar. 16 at 4:17 PM

$IOBT Purchases are going through Dark Poll, 100 thousand shares in 1 second

0 · Reply

VinnyLaw Mar. 16 at 4:03 PM

$IOBT It’s clear that there’s no buying pressure. I believed in the company, but since the announcement of sale, they have gone radio silent. Also, despite all allegations, the stock has been dropping like a stone without any support. There’s no one buying this at this time. It seems to me that this may indeed be heading to $0.

0 · Reply

GTMStox Mar. 16 at 3:33 PM

$IOBT This is in a very similar position to $QNCX

0 · Reply

LordWorld Mar. 16 at 3:18 PM

$IOBT With such volumes, if there weren’t so many buyers, IOBT would have been reset last week.

1 · Reply

LordWorld Mar. 16 at 2:57 PM

$IOBT Strong Buy

0 · Reply

Market Cap	13.78M
Revenue (ttm)	0.00
Net Income (ttm)	-95.49M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	18.31

Volume	2,449,200
Avg Vol	12,140,626
Day's Range	N/A - N/A
Shares Out	71.95M
Stochastic %K	17%
Beta	0.43
Analysts	Sell
Price Target	$1.62